Clearmind’s MEAI Included in U.S. Veterans’ Emerging Therapies Bill
Event summary
- Clearmind’s proprietary compound MEAI was named in the U.S. Congress’ Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).
- The bipartisan bill directs the VA to establish an investigational research and extended access treatment program for innovative therapies, including MEAI.
- If passed, H.R. 7091 would enable VA-supported clinical trials and extended access protocols for conditions like Alcohol Use Disorder (AUD) and PTSD.
- MEAI is Clearmind’s next-generation, non-hallucinogenic neuroplastogen, marking its first inclusion in U.S. federal legislation.
The big picture
The inclusion of MEAI in H.R. 7091 signals growing bipartisan support for psychedelic-assisted therapies in veteran healthcare, aligning with broader industry shifts toward evidence-based treatments for PTSD and AUD. Clearmind’s strategic positioning could expand if the bill passes, opening VA-funded research pathways and commercialization opportunities.
What we're watching
- Legislative Progress
- Whether H.R. 7091 advances through Congress and secures VA funding for MEAI trials.
- Clinical Validation
- The pace at which Clearmind can demonstrate MEAI’s efficacy in treating AUD and PTSD in veterans.
- Market Positioning
- How Clearmind leverages this legislative recognition to differentiate itself among psychedelic biotech peers.
Our editorial coverage:
Related topics